O -GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation
Proceedings of the National Academy of Sciences · 28.03.2023 · 120 (13)
DOI: 10.1073/pnas.2216796120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 21.03.2023. Verfasst von Qiang Zhu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang Provincial Key Laboratory of Pancreatic Disease, School o…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Tumor Escape. Die Arbeit wurde bisher 137-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Programmed-death ligand 1 (PD-L1) and its receptor programmed cell death 1 (PD-1) mediate T cell–dependent immunity against tumors. The abundance of cell surface PD-L1 is a key determinant of the efficacy of immune checkpoint blockade therapy targeting PD-L1. However, the regulation of cell surface PD-L1 is still poorly understood. Here, we show that lysosomal degradation of PD-L1 is regulated by O -linked N -acetylglucosamine ( O -GlcNAc) during the intracellular trafficking pathway. O -GlcNAc modifies the hepatocyte growth factor-regulated tyrosine kinase substrate (HGS), a key component of the endosomal sorting machinery, and subsequently inhibits its interaction with intracellular PD-L1, leading to impaired lysosomal degradation of PD-L1. O -GlcNAc inhibition activates T cell–mediated antitumor immunity in vitro and in immune-competent mice in a manner dependent on HGS glycosylation. Combination of O -GlcNAc inhibition with PD-L1 antibody synergistically promotes antitumor immune response. We also designed a competitive peptide inhibitor of HGS glycosylation that decreases PD-L1 expression and enhances T cell–mediated immunity against tumor cells. Collectively, our study reveals a link between O -GlcNAc and tumor immune evasion, and suggests strategies for improving PD-L1-mediated immune checkpoint blockade therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang Provincial Key Laboratory of Pancreatic Disease, School of Medicine, Zhejiang University, Hangzhou 310003, China.
- Department of Biochemistry, Ministry of Education Key Laboratory of Biosystems Homeostasis & Protection, College of Life Sciences, Zhejiang University, Hangzhou 310058, China.
- Cancer Center, Zhejiang University, Hangzhou 310058, China.
ORCID-Profile: Siyuan Chai, Wen Yi
Zitieren
APA
Zhu, Q., Wang, H., Chai, S., Xu, L., Lin, B., Yi, W., & Wu, L. (2023). O -GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation. Proceedings of the National Academy of Sciences, 120(13). https://doi.org/10.1073/pnas.2216796120
Vancouver
Zhu Q, Wang H, Chai S, Xu L, Lin B, Yi W, et al. O -GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation. Proceedings of the National Academy of Sciences. 2023;120(13). doi:10.1073/pnas.2216796120
BibTeX
@article{Zhu2023,
author = {Zhu, Qiang and Wang, Hongxing and Chai, Siyuan and Xu, Liang and Lin, Bingyi and Yi, Wen and Wu, Liming},
title = {O -GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation},
journal = {Proceedings of the National Academy of Sciences},
year = {2023},
volume = {120},
number = {13},
doi = {10.1073/pnas.2216796120}
}
EUVIMED